Overview
Jaguar Health Q3 net revenue flat year-over-year
Company reports Q3 net loss of $9.5 mln, a slight improvement from last year
Result Drivers
R&D EXPENSES - Decrease due to conclusion of Phase 3 OnTarget clinical trial
G&A expense increased by approximately $0.3 million, from $3.8 million for the quarter ended September 30, 2024
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$3.08 mln
Q3 Net Income
-$9.5 mln
Q3 Adjusted EBITDA
-$8.88 mln
Q3 Basic EPS
-$6.28
Q3 Operating Income
-$7.24 mln
Analyst Coverage
The one available analyst rating on the shares is "strong buy"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Jaguar Health Inc is $16.00, about 88.9% above its November 14 closing price of $1.78
Press Release: ID:nACSNw72Sa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
